Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Janz, Martin Dr. (4) Leisegang, Matthias Prof. Dr. rer. nat. (1) Lusatis, Simone (1) Mathas, Stephan Dr. (4) Pezzutto, Antonio Prof. Dr. (2) Selbach, Matthias Prof. Dr. (2) Uckert, Wolfgang Prof. Dr. (1) Walther, Wolfgang Prof. Dr. (1) Willimsky, Gerald Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (18) (-) Wollert-Wulf, Brigitte (2) (-) Biologie maligner Lymphome (2) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (18) Translationale Onkologie solider Tumore (1) 1992 (4) 1993 (7) 1994 (5) (-) 1995 (8) 1996 (6) (-) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) (-) 2006 (3) 2007 (5) 2008 (5) 2009 (2) 2010 (7) 2011 (5) 2012 (6) 2013 (13) 2014 (4) 2015 (4) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (6) 2024 (2) 20 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Wollert-Wulf, BrigitteBiologie maligner LymphomeMolekulare Immunologie und Gentherapie 199519972006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 1995 / Canc Res Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response Z. Qin T. Blankenstein 01. Januar 1995 / Canc Gene Ther Vectors in cancer therapy: how will they deliver M. Blaese T. Blankenstein M. Brenner O. Cohen-Haguenauer B. Gansbacher S. Russell B. Sorrentino T. Velu 01. Januar 1997 / Exp Hematol Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells A. Aicher J. Westermann S. Cayeux G. Willimsky K. Daemen T. Blankenstein W. Uckert B. Doerken A. Pezzutto 01. Januar 1997 / Methods Mol Med Methods for use of cytokine gene-modified tumor cells in immunotherapy of cancer Z. Qin T. Blankenstein 15. Juli 1997 / J Immunol Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells Z. Qin G. Noffz M. Mohaupt T. Blankenstein 15. Oktober 1997 / J Immunol Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis P.T. Daniel A. Kroidl S. Cayeux R.C. Bargou T. Blankenstein B. Doerken 01. Januar 1997 / J Immunol Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation S. Cayeux G. Richter G. Noffz B. Doerken T. Blankenstein 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken Seitennummerierung Erste Seite « First Vorherige Seite ‹ Previous Seite 1 Aktuelle Seite 2
01. Januar 1995 / Canc Res Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response Z. Qin T. Blankenstein
01. Januar 1995 / Canc Gene Ther Vectors in cancer therapy: how will they deliver M. Blaese T. Blankenstein M. Brenner O. Cohen-Haguenauer B. Gansbacher S. Russell B. Sorrentino T. Velu
01. Januar 1997 / Exp Hematol Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells A. Aicher J. Westermann S. Cayeux G. Willimsky K. Daemen T. Blankenstein W. Uckert B. Doerken A. Pezzutto
01. Januar 1997 / Methods Mol Med Methods for use of cytokine gene-modified tumor cells in immunotherapy of cancer Z. Qin T. Blankenstein
15. Juli 1997 / J Immunol Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells Z. Qin G. Noffz M. Mohaupt T. Blankenstein
15. Oktober 1997 / J Immunol Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis P.T. Daniel A. Kroidl S. Cayeux R.C. Bargou T. Blankenstein B. Doerken
01. Januar 1997 / J Immunol Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation S. Cayeux G. Richter G. Noffz B. Doerken T. Blankenstein
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken